OCT Angiography with the AngioVue system is also less costly to administer than FA and has fewer side effects. In short, AngioVue may be the future of retinal imaging.
Harlow, Essex (PRWEB UK) 21 August 2015
After a successful introduction of the revolutionary AngioVue imaging system at the ESCRS meeting in London in September 2014, Universities, hospitals and private clinics are eagerly adopting the technology. Many of the sales include recent installations into UK hospitals.
The AngioVue imaging system is a non-invasive, dyeless technique for visualising the presence of ocular flow in the vessels. AngioVue allows clinicians to assess microvasculature and perfusion in ocular diseases with unprecedented detail. Unlike other imaging methods which utilise contrast agents, AngioVue allows visualisation of microvasculature within specific layers of the retina, without the blurring or obscuring effects of staining or pooling.
“This ground-breaking technology provides clinicians with new information that complements Fluorescein Angiography (FA) and brings new elements to FA. In some cases AngioVue can replace FA,” said Professor Bruno Lumbroso, MD, Director, Centro Italiano Macula, Rome, Italy. “OCT Angiography with the AngioVue system is also less costly to administer than FA and has fewer side effects. In short, AngioVue may be the future of retinal imaging.”
The unique combination of two proprietary technologies has enabled Optovue to take AngioVue and OCT Angiography from clinical research into daily clinical practice. Patented Split Spectrum Amplitude Decorrelation Angiography (SSADA) enables both high-quality vascular imaging with a higher signal to noise ratio, and a reduced scan time of less than six seconds. Patented Motion Correction Technology (MCT™) minimises motion artefacts to further improve image quality.
To find out more about the AngioVue OCT-A system, please contact Haag-Streit UK on (01279) 883807 or visit http://www.haagstreituk.com/angiovue.